Marksans Pharma's consolidated revenue for the quarter came in at Rs. 215.2 crore, registering 1.1% yoy decline.
EBITDA for the quarter fell 5.9% yoy to Rs. 28.8 crore with a corresponding margin contraction of 69 bps. EBITDA margin for the quarter stood at 13.4%. This margin contraction was aided by increase in cost of materials consumed by 22.5% yoy.
PAT for the quarter came in at Rs. 12.8 crore, yoy decline of 31.2%. This was mainly due to tax expense of Rs. 2.3 crore in Q3FY17 vs tax credit of Rs. 0.1 crore in Q3FY16.
Technical View:
Marksans Pharma Ltd ended at Rs. 39.95, up by 0.85 points or 2.17% from its previous closing of Rs. 39.1 on the BSE.
The scrip opened at Rs. 39.5 and touched a high and low of Rs. 40.9 and Rs. 39.5 respectively. A total of 4835925(NSE+BSE) shares were traded on the counter. The stock traded above its 200 DMA.
EBITDA for the quarter fell 5.9% yoy to Rs. 28.8 crore with a corresponding margin contraction of 69 bps. EBITDA margin for the quarter stood at 13.4%. This margin contraction was aided by increase in cost of materials consumed by 22.5% yoy.
PAT for the quarter came in at Rs. 12.8 crore, yoy decline of 31.2%. This was mainly due to tax expense of Rs. 2.3 crore in Q3FY17 vs tax credit of Rs. 0.1 crore in Q3FY16.
Technical View:
Marksans Pharma Ltd ended at Rs. 39.95, up by 0.85 points or 2.17% from its previous closing of Rs. 39.1 on the BSE.
The scrip opened at Rs. 39.5 and touched a high and low of Rs. 40.9 and Rs. 39.5 respectively. A total of 4835925(NSE+BSE) shares were traded on the counter. The stock traded above its 200 DMA.